11:04 AM EDT, 04/30/2025 (MT Newswires) -- Lantheus ( LNTH ) said Wednesday its radiodiagnostic MK-6240 to treat Alzheimer's disease met its co-primary endpoints in two trials evaluating its sensitivity and specificity.

The results from the two trials will back a new drug application with the US Food and Drug Administration, which is expected to be filed in Q3, the company said.

MK-6240 was designed to complement Lantheus' ( LNTH ) imaging agent NAV-4694, which is in phase 3 development and is used in academic and industry-led investigational trials for Alzheimer's disease, the company said.

The company's shares were down 0.5% in recent trading.

Price: 103.00, Change: -0.96, Percent Change: -0.93